According to the latest report by IMARC Group, titled "Oncology Injectables Market Report by Molecule Type (Small Molecule, Large Molecule), Product Type (Chemotherapy, Monoclonal Antibodies, Cytokines, Peptide Hormones), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, and Others), Branded/Generics (Branded, Generics), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and Region 2025-2033," the global oncology injectables market size reached USD 174.8 Billion in 2024. Oncology injectables are intravenous drugs that are widely used for the treatment of different forms of cancer. These drugs are administered directly in the bloodstream of the patient to improve its biological effect. Extensively available in liquid form, these injectables aid in mitigating the growth of cancer-inducing proteins while destroying the malignant cells formed in the body. These drugs are usually preferred by healthcare professionals for cancer treatments as they provide improved efficiency, increased bioavailability, better compliance and reduced gastrointestinal irritation.
Global Oncology Injectables Market Trends:
The market is primarily driven by the increasing prevalence of various forms of cancer across the globe. This, along with the growing awareness regarding early cancer detection among the masses, is providing a thrust to the market growth. This is further supported by the easy accessibility to chemotherapy treatments and improving healthcare infrastructure on the global level. There has been a significant increase in the investments by drug manufacturers and biotechnology companies for developing new anti-cancer intravenous drugs, which is acting as another major growth-inducing factor. These injectables are expected to be highly efficient and target-oriented with minimal side effects. This, coupled with the faster drug approvals from several regulatory bodies, including the US Food and Drug Administration (FDA), is anticipated to create a positive outlook for the market. Moreover, the growing preference for multiple generic oncology injectables by patients on account of the cost-efficient nature of these drugs is providing an impetus to the market growth. Some of the other factors contributing to the market growth include the increasing penetration of healthcare insurance and the rising trend of medical tourism on the global level. Looking forward, the market value is projected to reach USD 414.5 Billion by 2033, expanding at a CAGR of 9.57% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Molecule Type, Product Type, Indication, Branded/Generics, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico, Turkey, Saudi Arabia |
Companies Covered | Amgen, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co. Inc. and Sanofi S.A. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800